Patents by Inventor Amnon Hoffman

Amnon Hoffman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220119474
    Abstract: The present invention provides peptides derived from the cytoplasmic region of protease-activated receptors 4 (PAR4) as well as analogs and cyclic analogs, such as backbone cyclic analogs, of these peptides. Pharmaceutical compositions comprising said peptides, analog, cyclic analogs and well as conjugates thereof are provides as well. The peptides, analogs and conjugates of the present invention and pharmaceutical composition comprising thereof have several uses including treating cancer and inhibiting interactions between PARs and protein comprising PH-domain.
    Type: Application
    Filed: February 19, 2020
    Publication date: April 21, 2022
    Inventors: Rachel BAR-SHAVIT, Chaim GILON, Amnon HOFFMAN
  • Patent number: 11261215
    Abstract: The present invention provides prodrugs of somatostatin peptide and peptide analogs that are tissue permeable and oral bioavailable and enable activity of the somatostatin analog at the circulation or target tissue after cleavage of charge-masking lipophilic moieties. Pharmaceutical compositions comprising these prodrugs and their use in therapy and diagnosis are also provided.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: March 1, 2022
    Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Amnon Hoffman, Chaim Gilon, Adi Klinger, Johnny Naoum
  • Publication number: 20220016218
    Abstract: The present invention relates to methods of preparing peptide-based prodrugs having enhanced oral bioavailability and intestinal penetration. Said prodrugs are characterized in improved lipophilicity, reduced electric charge and tendency to undergo biotransformation through enzymatic reaction (e.g. in the blood stream) to form biologically active peptides.
    Type: Application
    Filed: July 9, 2021
    Publication date: January 20, 2022
    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Amnon HOFFMAN, Chaim GILON, Joseph FANOUS, Adi KLINGER
  • Publication number: 20210315803
    Abstract: Provided herein are compositions of injectable antibiotics for veterinary use. The compositions are characterized by forming a gel at animal physiological temperature, said gel being characterized by a stable and repeatable release profile of the antibiotic. The compositions comprise high loading of drug in poloxamer solutions with addition of a co-solvent, and preferably with an addition of a cellulose derivative at least partially soluble in organic solvents. Methods of treatment of veterinary infections are also provided.
    Type: Application
    Filed: September 5, 2019
    Publication date: October 14, 2021
    Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Michael FRIEDMAN, David KIRMAYER, Zakhar NUDELMAN, Amnon HOFFMAN, Eran LAVY, Ayala BAR-HAI, Irith GATI
  • Patent number: 11052043
    Abstract: A composition which comprises a biologically active agent and a polymer that exhibits a reverse thermal gelation at a physiological temperature, in a carrier, and in which the active agent is in an undissolved form is disclosed herein. Further disclosed herein are methods utilizing the compositions for treating subjects, including non-human subjects, as well as kits for preparing and using a composition. The composition is preferably a sustained release formulation, and is particularly useful for treating animals, where single-dose treatment is desired.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: July 6, 2021
    Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Michael Friedman, Amnon Hoffman, Eran Lavy
  • Publication number: 20200323962
    Abstract: The present invention relates to methods of preparing peptide-based prodrugs having enhanced oral bioavailability and intestinal penetration. Said prodrugs are characterized in improved lipophilicity, reduced electric charge and tendency to undergo biotransformation through enzymatic reaction (e.g. in the blood stream) to form biologically active peptides.
    Type: Application
    Filed: September 17, 2018
    Publication date: October 15, 2020
    Inventors: Amnon HOFFMAN, Chaim GILON, Joseph FANOUS, Adi KLINGER
  • Publication number: 20200283483
    Abstract: The present invention provides N-methylated cyclic hexapeptides comprising RGD and at least one alanine residue. The present invention further provides prodrugs comprising the cyclic hexapeptides. Pharmaceutical compositions comprising said cyclic hexapeptides are also disclosed as well as methods of their production and use in treating integrin related conditions and diseases.
    Type: Application
    Filed: September 17, 2018
    Publication date: September 10, 2020
    Inventors: Horst Otto KESSLER, Chaim GILON, Amnon HOFFMAN, Michael WEINMULLER, Florian RECHENMACHER, Joseph FANOUS, Adi KLINGER
  • Publication number: 20200262871
    Abstract: The present invention provides prodrugs of somatostatin peptide and peptide analogs that are tissue permeable and oral bioavailable and enable activity of the somatostatin analog at the circulation or target tissue after cleavage of charge-masking lipophilic moieties. Pharmaceutical compositions comprising these prodrugs and their use in therapy and diagnosis are also provided.
    Type: Application
    Filed: September 17, 2018
    Publication date: August 20, 2020
    Inventors: Amnon HOFFMAN, Chaim GILON, Adi KLINGER, Johnny NAOUM
  • Patent number: 10662225
    Abstract: Provided are backbone cyclized peptides that interfere with signaling of the intracellular adaptor protein MyD88. Pharmaceutical compositions including these backbone cyclized peptides as well as their use in treatment of multiple sclerosis (MS) and other diseases associated with MyD88 signaling are also disclosed.
    Type: Grant
    Filed: June 4, 2017
    Date of Patent: May 26, 2020
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Gabriel Nussbaum, Amnon Hoffman, Chaim Gilon
  • Publication number: 20200009067
    Abstract: Provided is a formulation and method for increasing bioavailability of an orally administered drug.
    Type: Application
    Filed: September 20, 2019
    Publication date: January 9, 2020
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Amnon HOFFMAN, Abraham J. DOMB, Anna ELGART, Irina CHERNIAKOV
  • Publication number: 20190185516
    Abstract: Provided are backbone cyclized peptides that interfere with signaling of the intracellular adaptor protein MyD88. Pharmaceutical compositions including these backbone cyclized peptides as well as their use in treatment of multiple sclerosis (MS) and other diseases associated with MyD88 signaling are also disclosed.
    Type: Application
    Filed: June 4, 2017
    Publication date: June 20, 2019
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Gabriel NUSSBAUM, Amnon HOFFMAN, Chaim GILON
  • Publication number: 20180325861
    Abstract: Provided are formulations and methods for improving oral bioavailability of cannabinoid compositions.
    Type: Application
    Filed: October 26, 2016
    Publication date: November 15, 2018
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventors: Abraham J. DOMB, Amnon HOFFMAN, Dvora IZGELOV
  • Patent number: 9725484
    Abstract: The present invention relates to methods and compositions for treating disease related to disorders of bone remodeling. In particular, the present invention relates to compositions and methods for treating rheumatoid arthritis.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: August 8, 2017
    Assignees: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD.
    Inventors: Joseph Holoshitz, Song Ling, Chaim Gilon, Amnon Hoffman
  • Patent number: 9555086
    Abstract: The present invention provides compositions and methods for inducing an immune response in a subject. In particular, the present invention provides compositions comprising immunostimulatory ligands (ISL) and methods of inducing an immune response in a subject therewith. Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: January 31, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Joseph Holoshitz, Song Ling, Xiujun Pi, Denise de Almeida, Chaim Gilon, Amnon Hoffman
  • Publication number: 20160002295
    Abstract: The present invention relates to methods and compositions for treating disease related to disorders of bone remodeling. In particular, the present invention relates to compositions and methods for treating rheumatoid arthritis.
    Type: Application
    Filed: February 24, 2014
    Publication date: January 7, 2016
    Inventors: Joseph Holoshitz, Song Ling, Chaim Gilon, Amnon Hoffman
  • Patent number: 8993544
    Abstract: The present invention relates to novel metalloproteinase inhibitors having an aryloxybenzenesulfonamide moiety and a carbamoylphosphonic acid moiety, to pharmaceutical compositions comprising them, and to their uses in the prevention and/or treatment of disease or disorder associated with MMP.
    Type: Grant
    Filed: February 9, 2010
    Date of Patent: March 31, 2015
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.
    Inventors: Eli Breuer, Reuven Reich, Julia Frant, Amnon Hoffman, Veerendhar Ainelly
  • Publication number: 20140348926
    Abstract: The application discloses a formulation and method for increasing bioavailability of an orally administered drug.
    Type: Application
    Filed: January 17, 2013
    Publication date: November 27, 2014
    Inventors: Amnon Hoffman, Abraham J. Domb, Anna Elgart, Irina Cherniakov
  • Publication number: 20140212444
    Abstract: The present invention provides compositions and methods for inducing an immune response in a subject. In particular, the present invention provides compositions comprising immunostimulatory ligands (ISL) and methods of inducing an immune response in a subject therewith. Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.
    Type: Application
    Filed: January 27, 2014
    Publication date: July 31, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Joseph Holoshitz, Song Ling, Xiujun Pi, Denise de Almeida, Chaim Gilon, Amnon Hoffman
  • Patent number: 8658603
    Abstract: The present invention provides compositions and methods for inducing an immune response in a subject. In particular, the present invention provides compositions comprising immunostimulatory ligands (ISL) and methods of inducing an immune response in a subject therewith. Compositions and methods of the present invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine (e.g., vaccination)) and research applications.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: February 25, 2014
    Assignee: The Regents of the University of Michigan
    Inventors: Joseph Holoshitz, Song Ling, Xiujun Pi, Denise de Almeida, Chaim Gilon, Amnon Hoffman
  • Publication number: 20140018323
    Abstract: A composition which comprises a biologically active agent and a polymer that exhibits a reverse thermal gelation at a physiological temperature, in a carrier, and in which the active agent is in an undissolved form is disclosed herein. Further disclosed herein are methods utilizing the compositions for treating subjects, including non-human subjects, as well as kits for preparing and using a composition. The composition is preferably a sustained release formulation, and is particularly useful for treating animals, where single-dose treatment is desired.
    Type: Application
    Filed: March 28, 2012
    Publication date: January 16, 2014
    Inventors: Michael Friedman, Amnon Hoffman, Eran Lavy